{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T20:33:17Z","timestamp":1764102797640,"version":"3.40.5"},"reference-count":74,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["nmcd-journal.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1016\/j.numecd.2016.07.004","type":"journal-article","created":{"date-parts":[[2016,7,15]],"date-time":"2016-07-15T03:30:00Z","timestamp":1468553400000},"page":"980-986","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"title":["Lp(a) and cardiovascular risk: Investigating the hidden side of the moon"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5213-7768","authenticated-orcid":false,"given":"M.","family":"Bucci","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Tana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.A.","family":"Giamberardino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Cipollone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.numecd.2016.07.004_bib1","series-title":"Braunwald's heart disease: a textbook of cardiovascular medicine","first-page":"927","article-title":"Risk markers for atherothrombotic disease","author":"Ridker","year":"2012"},{"issue":"5","key":"10.1016\/j.numecd.2016.07.004_bib2","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1194\/jlr.R060582","article-title":"Lipoprotein(a): truly a direct prothrombotic factor in cardiovascular disease?","volume":"57","author":"Boffa","year":"2016","journal-title":"J Lipid Res"},{"key":"10.1016\/j.numecd.2016.07.004_bib3","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1161\/01.ATV.18.9.1393","article-title":"Apolipoprotein(a) enhances platelet responses to the thrombin receptor-activating peptide SFLLRN","volume":"18","author":"Sangrar","year":"1998","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.numecd.2016.07.004_bib4","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1055\/s-0037-1615654","article-title":"Binding of recombinant apolipoprotein(a) to human platelets and effect on platelet aggregation","volume":"85","author":"Martinez","year":"2001","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.numecd.2016.07.004_bib5","doi-asserted-by":"crossref","first-page":"4628","DOI":"10.1021\/bi00068a021","article-title":"Lipoprotein(a) binds to human platelets and attenuates plasminogen binding and activation","volume":"32","author":"Ezratty","year":"1993","journal-title":"Biochemistry"},{"key":"10.1016\/j.numecd.2016.07.004_bib6","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1182\/blood.V98.10.2980","article-title":"Lipoprotein (a) binds and inactivates tissue factor pathway inhibitor: a novel link between lipoproteins and thrombosis","volume":"98","author":"Caplice","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.numecd.2016.07.004_bib7","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1111\/j.1538-7836.2007.02637.x","article-title":"Altered fibrin clot structure in patients with advanced coronary artery disease: a role of C-reactive protein, lipoprotein(a) and homocysteine","volume":"5","author":"Undas","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.numecd.2016.07.004_bib8","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1172\/JCI116983","article-title":"Impairment of endothelium-dependent dilation is an early event in children with familial hypercholesterolemia and is related to the lipoprotein(a) level","volume":"93","author":"Sorensen","year":"1994","journal-title":"J Clin Invest"},{"key":"10.1016\/j.numecd.2016.07.004_bib9","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/S0735-1097(97)00237-4","article-title":"Lipoprotein(a) selectively impairs receptor-mediated endothelial vasodilator function of the human coronary circulation","volume":"30","author":"Schachinger","year":"1997","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.numecd.2016.07.004_bib10","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1194\/jlr.M800174-JLR200","article-title":"A novel function of lipoprotein [a] as a preferential carrier of oxidized phospholipids in human plasma","volume":"49","author":"Bergmark","year":"2008","journal-title":"J Lipid Res"},{"key":"10.1016\/j.numecd.2016.07.004_bib11","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/j.jacc.2011.12.033","article-title":"Oxidized phospholipids are present on plasminogen, affect fibrinolysis, and increase following acute myocardial infarction","volume":"59","author":"Leibundgut","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.numecd.2016.07.004_bib12","doi-asserted-by":"crossref","first-page":"673","DOI":"10.2217\/bmm.11.60","article-title":"Oxidized phospholipids on apoB-100-containing lipoproteins: a biomarker predicting cardiovascular disease and cardiovascular events","volume":"5","author":"Taleb","year":"2011","journal-title":"Biomark Med"},{"key":"10.1016\/j.numecd.2016.07.004_bib13","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/339303a0","article-title":"Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis","volume":"339","author":"Hajjar","year":"1989","journal-title":"Nature"},{"key":"10.1016\/j.numecd.2016.07.004_bib14","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1194\/jlr.M036566","article-title":"Inhibition of plasminogen activation by apo(a): role of carboxyl-terminal lysines and identification of inhibitory domains in apo(a)","volume":"55","author":"Romagnuolo","year":"2014","journal-title":"J Lipid"},{"key":"10.1016\/j.numecd.2016.07.004_bib15","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1111\/j.1538-7836.2008.03183.x","article-title":"Apolipoprotein(a) inhibits the conversion of Glu-plasminogen to Lys-plasminogen: a novel mechanism for lipoprotein(a)-mediated inhibition of plasminogen activation","volume":"6","author":"Feric","year":"2008","journal-title":"J Thromb Haemost"},{"issue":"2","key":"10.1016\/j.numecd.2016.07.004_bib16","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S0021-9150(99)00285-3","article-title":"Sequence conservation in kringle IV-type 2 repeats of the LPA gene","volume":"148","author":"R\u00f8sby","year":"2000","journal-title":"Atherosclerosis"},{"issue":"4","key":"10.1016\/j.numecd.2016.07.004_bib17","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1093\/hmg\/2.4.361","article-title":"The apolipoprotein(a) kringle IV repeats which differ from the major repeat kringle are present in variably-sized isoforms","volume":"2","author":"van der Hoek","year":"1993","journal-title":"Hum Mol Genet"},{"issue":"1","key":"10.1016\/j.numecd.2016.07.004_bib18","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/BF02827238","article-title":"Lipoprotein(a): structural implications for pathophysiology","volume":"27","author":"Koschinsky","year":"1997","journal-title":"Int J Clin Lab Res"},{"issue":"10","key":"10.1016\/j.numecd.2016.07.004_bib19","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1038\/sj.ki.5002240","article-title":"Evidence mounts for a role of the kidney in lipoprotein(a) catabolism","volume":"71","author":"Albers","year":"2007","journal-title":"Kidney Int"},{"issue":"9","key":"10.1016\/j.numecd.2016.07.004_bib20","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1172\/JCI119753","article-title":"The atherogenic lipoprotein Lp(a) is internalized and degraded in a process mediated by the VLDL receptor","volume":"100","author":"Argraves","year":"1997","journal-title":"J Clin Invest"},{"issue":"6","key":"10.1016\/j.numecd.2016.07.004_bib21","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1161\/01.ATV.16.6.713","article-title":"Apolipoprotein(a) kringle IV repeat number predicts risk for coronary heart disease","volume":"16","author":"Kraft","year":"1996","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"2","key":"10.1016\/j.numecd.2016.07.004_bib22","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1093\/ije\/dyv071","article-title":"Mendelian randomization studies: a review of the approaches used and the quality of reporting","volume":"44","author":"Boef","year":"2015","journal-title":"Int J Epidemiol"},{"issue":"12","key":"10.1016\/j.numecd.2016.07.004_bib23","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.7326\/0003-4819-120-12-199406150-00008","article-title":"Quantitation of plasma apolipoproteins in the primary and secondary prevention of coronary artery disease","volume":"120","author":"Rader","year":"1994","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.numecd.2016.07.004_bib24","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0022-2275(20)41683-9","article-title":"Radioimmunoassay of human plasma Lp(a) lipoprotein","volume":"18","author":"Albers","year":"1977","journal-title":"J Lipid Res"},{"issue":"4","key":"10.1016\/j.numecd.2016.07.004_bib25","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1161\/01.CIR.87.4.1135","article-title":"Effects of age, sex, and menopausal status on plasma lipoprotein(a) levels. The Framingham Offspring Study","volume":"87","author":"Jenner","year":"1993","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.numecd.2016.07.004_bib26","first-page":"119","article-title":"Quantification of lipoprotein(a): comparison of an automated latex-enhanced nephelometric assay with an immunoenzymometric method","volume":"34","author":"Schmidt","year":"1996","journal-title":"Eur J Clin Chem Clin Biochem"},{"issue":"2","key":"10.1016\/j.numecd.2016.07.004_bib27","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/jcla.1860070207","article-title":"Automated latex nephelometric immunoassay for the measurement of serum lipoprotein (a)","volume":"7","author":"Borque","year":"1993","journal-title":"J Clin Lab Anal"},{"issue":"3","key":"10.1016\/j.numecd.2016.07.004_bib28","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1093\/clinchem\/39.3.503","article-title":"Rate nephelometric assay of serum lipoprotein(a)","volume":"39","author":"Gillery","year":"1993","journal-title":"Clin Chem"},{"issue":"12","key":"10.1016\/j.numecd.2016.07.004_bib29","first-page":"869","article-title":"Automated turbidimetry of serum lipoprotein(a)","volume":"31","author":"Borque","year":"1993","journal-title":"Eur J Clin Chem Clin Biochem"},{"key":"10.1016\/j.numecd.2016.07.004_bib30","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/jama.2009.1063","article-title":"Lipoprotein(a) concentration and the risk of coronary heart disease, stroke and nonvascular mortality","volume":"302","author":"Erqou","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.numecd.2016.07.004_bib31","doi-asserted-by":"crossref","first-page":"923289","DOI":"10.1155\/2012\/923289","article-title":"Lipoprotein(a): cellular effects and molecular mechanisms","volume":"2012","author":"Riches","year":"2012","journal-title":"Cholesterol"},{"issue":"2","key":"10.1016\/j.numecd.2016.07.004_bib32","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0021-9150(86)90048-1","article-title":"Lp(a) lipoprotein as a risk factor for coronary heart disease and cerebral infarction","volume":"59","author":"Murai","year":"1986","journal-title":"Atherosclerosis"},{"issue":"3","key":"10.1016\/j.numecd.2016.07.004_bib33","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1159\/000319065","article-title":"Increased stroke risk and lipoprotein(a) in a multiethnic community: the Northern Manhattan Stroke Study","volume":"30","author":"Boden-Albala","year":"2010","journal-title":"Cerebrovasc Dis"},{"issue":"11","key":"10.1016\/j.numecd.2016.07.004_bib34","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/j.mayocp.2013.09.003","article-title":"Lipoprotein(a), cardiovascular disease, and contemporary management","volume":"88","author":"Jacobson","year":"2013","journal-title":"Mayo Clin Proc"},{"issue":"6","key":"10.1016\/j.numecd.2016.07.004_bib35","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.jacc.2013.09.042","article-title":"Lipoprotein(a) for risk assessment in patients with established coronary artery disease","volume":"63","author":"O'Donoghue","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.numecd.2016.07.004_bib36","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.atherosclerosis.2013.01.014","article-title":"Association between baseline lipoprotein (a) levels and restenosis after coronary stenting: meta-analysis of 9 cohort studies","volume":"227","author":"Qin","year":"2013","journal-title":"Atherosclerosis"},{"issue":"6","key":"10.1016\/j.numecd.2016.07.004_bib37","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1161\/STROKEAHA.106.480657","article-title":"Lipoprotein (a) and stroke: a meta-analysis of observational studies","volume":"38","author":"Smolders","year":"2007","journal-title":"Stroke"},{"issue":"2","key":"10.1016\/j.numecd.2016.07.004_bib38","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.atherosclerosis.2015.08.021","article-title":"Lipoprotein (a) as a risk factor for ischemic stroke: a meta-analysis","volume":"242","author":"Nave","year":"2015","journal-title":"Atherosclerosis"},{"issue":"5","key":"10.1016\/j.numecd.2016.07.004_bib39","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1007\/BF02002128","article-title":"Lipoprotein (a): a risk factor for peripheral vascular disease","volume":"7","author":"Widmann","year":"1993","journal-title":"Ann Vasc Surg"},{"issue":"7","key":"10.1016\/j.numecd.2016.07.004_bib40","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1373\/clinchem.2007.088013","article-title":"Increased serum lipoprotein(a) concentrations and low molecular weight phenotypes of apolipoprotein(a) are associated with symptomatic peripheral arterial disease","volume":"53","author":"Dieplinger","year":"2007","journal-title":"Clin Chem"},{"issue":"4","key":"10.1016\/j.numecd.2016.07.004_bib41","doi-asserted-by":"crossref","first-page":"344","DOI":"10.5551\/jat.25478","article-title":"Lp(a) and lipid abnormalities are critical risk factors for CAD in Japanese patients with PAD","volume":"22","author":"Kumakura","year":"2015","journal-title":"J Atheroscler Thromb"},{"issue":"3","key":"10.1016\/j.numecd.2016.07.004_bib42","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1093\/eurheartj\/ehl441","article-title":"Inflammatory, haemostatic, and rheological markers for incident peripheral arterial disease: Edinburgh Artery Study","volume":"28","author":"Tzoulaki","year":"2007","journal-title":"Eur Heart J"},{"issue":"12","key":"10.1016\/j.numecd.2016.07.004_bib43","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1161\/ATVBAHA.112.255521","article-title":"Lipoprotein(a) and risk of coronary, cerebrovascular, and peripheral artery disease: the EPIC-Norfolk prospective population study","volume":"32","author":"Gurdasani","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"10.1016\/j.numecd.2016.07.004_bib44","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1510\/icvts.2009.208843","article-title":"Circulating lipoprotein(a) concentrations and abdominal aortic aneurysm presence","volume":"9","author":"Takagi","year":"2009","journal-title":"Interact Cardiovasc Thorac Surg"},{"key":"10.1016\/j.numecd.2016.07.004_bib45","doi-asserted-by":"crossref","DOI":"10.1093\/ehjci\/jev338","article-title":"Lipoprotein(a) is a risk factor for aortic and mitral valvular stenosis in peripheral arterial disease","author":"Hojo","year":"2016","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.numecd.2016.07.004_bib46","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.atherosclerosissup.2015.02.032","article-title":"Lipoprotein apheresis in patients with peripheral artery disease and hyperlipoproteinemia(a)","volume":"18","author":"Poller","year":"2015","journal-title":"Atheroscler Suppl"},{"issue":"2","key":"10.1016\/j.numecd.2016.07.004_bib47","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.jvs.2015.08.114","article-title":"Sex and ethnic differences in the associations between lipoprotein(a) and peripheral arterial disease in the multi-ethnic study of atherosclerosis","volume":"63","author":"Forbang","year":"2016","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.numecd.2016.07.004_bib48","doi-asserted-by":"crossref","DOI":"10.1161\/ATVBAHA.115.306647","article-title":"Lipoprotein-associated phospholipase A2 and Incident peripheral arterial disease in older adults: the cardiovascular health study","author":"Garg","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"10.1016\/j.numecd.2016.07.004_bib49","first-page":"41","article-title":"Elevated lipoprotein(a) (LP(a)) levels have been shown to be an important risk factor for CVD. Lp(a) levels: effects of progressive chronic renal failure and dietary manipulation","volume":"10","author":"Monzani","year":"1997","journal-title":"J Nephrol"},{"key":"10.1016\/j.numecd.2016.07.004_bib50","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ijcard.2015.12.007","article-title":"Plasma lipoprotein(a) predicts major cardiovascular events in patients with chronic kidney disease who undergo percutaneous coronary intervention","volume":"205","author":"Konishi","year":"2016","journal-title":"Int J Cardiol"},{"issue":"1","key":"10.1016\/j.numecd.2016.07.004_bib51","first-page":"41","article-title":"Lp(a) levels: effects of progressive chronic renal failure and dietary manipulation","volume":"10","author":"Monzani","year":"1997","journal-title":"J Nephrol"},{"issue":"3","key":"10.1016\/j.numecd.2016.07.004_bib52","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/eurheartj\/ehr350","article-title":"Genetic variants, plasma lipoprotein(a) levels, and risk of cardiovascular morbidity and mortality among two prospective cohorts of type 2 diabetes","volume":"33","author":"Qi","year":"2012","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.numecd.2016.07.004_bib53","doi-asserted-by":"crossref","first-page":"332","DOI":"10.2337\/db13-1144","article-title":"The association between circulating lipoprotein(a) and type 2 diabetes: is it causal?","volume":"63","author":"Ye","year":"2014","journal-title":"Diabetes"},{"issue":"6","key":"10.1016\/j.numecd.2016.07.004_bib54","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa1109034","article-title":"Genetic associations with valvular calcification and aortic stenosis","volume":"368","author":"Thanassoulis","year":"2013","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.numecd.2016.07.004_bib55","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1210\/jc.2015-1096","article-title":"Elevated lipoprotein(a) does not cause low-grade inflammation despite causal association with aortic valve stenosis and myocardial infarction: a study of 100,578 individuals from the general population","volume":"100","author":"Langsted","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.numecd.2016.07.004_bib56","article-title":"Lipoprotein(a) in calcific aortic valve disease: from genomics to novel drug target for aortic stenosis","author":"Thanassoulis","year":"2015","journal-title":"J Lipid Res"},{"issue":"5","key":"10.1016\/j.numecd.2016.07.004_bib57","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.jacc.2013.09.038","article-title":"Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population","volume":"63","author":"Kamstrup","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.numecd.2016.07.004_bib58","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1161\/CIRCGENETICS.113.000400","article-title":"Lipoprotein(a) levels, genotype, and incident aortic valve stenosis: a prospective Mendelian randomization study and replication in a case-control cohort","volume":"7","author":"Arsenault","year":"2014","journal-title":"Circ Cardiovasc Genet"},{"issue":"19","key":"10.1016\/j.numecd.2016.07.004_bib59","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1016\/j.jacc.2009.12.048","article-title":"The mysteries of lipoprotein(a) and cardiovascular disease revisited","volume":"55","author":"Kiechl","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.numecd.2016.07.004_bib60","doi-asserted-by":"crossref","first-page":"g4774","DOI":"10.1136\/bmj.g4774","article-title":"Niacin fails to reduce vascular events in large randomised trial","volume":"349","author":"McCarthy","year":"2014","journal-title":"BMJ"},{"issue":"9","key":"10.1016\/j.numecd.2016.07.004_bib61","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1093\/clinchem\/48.9.1454","article-title":"Effect of aspirin treatment on serum concentrations of lipoprotein(a) in patients with atherosclerotic diseases","volume":"48","author":"Akaike","year":"2002","journal-title":"Clin Chem"},{"issue":"3","key":"10.1016\/j.numecd.2016.07.004_bib62","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.jacl.2015.11.014","article-title":"Evacetrapib alone or in combination with statins lowers lipoprotein(a) and total and small LDL particle concentrations in mildly hypercholesterolemic patients","volume":"10","author":"Nicholls","year":"2016","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.numecd.2016.07.004_bib63","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.atherosclerosis.2016.03.017","article-title":"Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib in Japanese patients with heterozygous familial hypercholesterolemia","volume":"249","author":"Arai","year":"2016","journal-title":"Atherosclerosis"},{"issue":"23","key":"10.1016\/j.numecd.2016.07.004_bib64","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1016\/j.jacc.2013.07.081","article-title":"Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hyper-cholesterolemia at\u00a0high cardiovascular risk: a randomized, double-blind, placebo-con- trolled trial","volume":"62","author":"Thomas","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.numecd.2016.07.004_bib65","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1056\/NEJMoa061189","article-title":"Inhibition of microsomal triglyceride transfer protein in familial hy- percholesterolemia","volume":"356","author":"Cuchel","year":"2007","journal-title":"N Engl J Med"},{"issue":"9860","key":"10.1016\/j.numecd.2016.07.004_bib66","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(12)61731-0","article-title":"Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study","volume":"381","author":"Cuchel","year":"2013","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.numecd.2016.07.004_bib67","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1161\/CIRCULATIONAHA.113.001969","volume":"128","author":"Desai","year":"2013","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.numecd.2016.07.004_bib68","doi-asserted-by":"crossref","first-page":"234e43","DOI":"10.1161\/CIRCULATIONAHA.113.007012","article-title":"Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52- week results from the open-label study of long-term evaluation against LDL-C (OSLER) randomized trial","volume":"129","author":"Koren","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.numecd.2016.07.004_bib69","doi-asserted-by":"crossref","first-page":"263e267","DOI":"10.1016\/j.atherosclerosissup.2015.02.039","article-title":"Lipoprotein(a) e an independent causal risk factor for cardiovascular disease and current therapeutic options","volume":"18","author":"Kassner","year":"2015","journal-title":"Atheroscler Suppl"},{"key":"10.1016\/j.numecd.2016.07.004_bib70","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/ncpcardio1456","article-title":"Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events","volume":"6","author":"Jaeger","year":"2009","journal-title":"Nat Clin Pract Cardiovasc Med"},{"issue":"24","key":"10.1016\/j.numecd.2016.07.004_bib71","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1161\/CIRCULATIONAHA.113.002432","article-title":"Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease: prospective observational multicenter study","volume":"128","author":"Leebmann","year":"2013","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.numecd.2016.07.004_bib72","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.ejim.2011.06.015","article-title":"Antisense therapy in the treatment of hypercholesterolemia","volume":"22","author":"Lippi","year":"2011","journal-title":"Eur J Intern Med"},{"issue":"15","key":"10.1016\/j.numecd.2016.07.004_bib73","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1016\/j.jacc.2010.10.052","article-title":"Antisense oligonucleotide lowers plasma levels of apolipoprotein (a) and lipoprotein (a) in transgenic mice","volume":"57","author":"Merki","year":"2011","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.numecd.2016.07.004_bib74","doi-asserted-by":"crossref","first-page":"560e8","DOI":"10.1097\/MOL.0b013e3283598d81","article-title":"Emerging therapeutic agents to lower lipoprotein(a) levels","volume":"23","author":"Kolski","year":"2012","journal-title":"Curr Opin Lipidol"}],"container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939475316301119?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939475316301119?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,3]],"date-time":"2022-07-03T03:38:51Z","timestamp":1656819531000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939475316301119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":74,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["S0939475316301119"],"URL":"https:\/\/doi.org\/10.1016\/j.numecd.2016.07.004","relation":{},"ISSN":["0939-4753"],"issn-type":[{"type":"print","value":"0939-4753"}],"subject":[],"published":{"date-parts":[[2016,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lp(a) and cardiovascular risk: Investigating the hidden side of the moon","name":"articletitle","label":"Article Title"},{"value":"Nutrition, Metabolism and Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.numecd.2016.07.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Italian Society of Diabetology, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition, and the Department of Clinical Medicine and Surgery, Federico II University. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}